Skip to content

ETF·NYSE

State Street SPDR S&P Biotech ETF (XBI)

$140.18 -3.94 (-2.73%)
At close: Nov 20, 4:00 PM EST
Hold
45 / 100
CleaRank Financial AI scorei
Net assets
$10.36B
Expense ratio
0.35%
Yield
0.35%
52-week range
$117.11 $169.89

What moved State Street SPDR S&P Biotech ETF (XBI)

Updated . Market figures as of November 20, 2026.

Was it the market or the fund?

On November 20, 2026, XBI fell 2.73%. The same day the S&P 500 (SPY) fell 3.64% and the Nasdaq 100 (QQQ) fell 5.67%.

The move was in line with the market. XBI's one-year beta to SPY is 1.18, so SPY's -3.64% would on average have meant -4.29% for XBI, close to what it did (1.6 percentage points less).

Over the last 20 sessions XBI is down 6.26% against -9.23% for SPY, 3.0 percentage points ahead of it.

The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)

Moves to November 20, 2026, side by side
That day 5 sessions 20 sessions
XBI -2.73% -6.89% -6.26%
S&P 500 (SPY) -3.64% -8.56% -9.23%
Nasdaq 100 (QQQ) -5.67% -10.51% -13.62%

Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.

What changed since November 19, 2026

  • CleaRank score: 49/100 on November 19, 2026, 45/100 on November 20, 2026 (still Hold).
  • The price is below its 200-day average on November 20, 2026 ($140.18 against $143.45); on November 19, 2026 it was above it.

After moves like this

XBI fell 2.73% on November 20, 2026. Its typical daily move over the 60 trading days before was 1.15%. Between October 6, 2016 and November 20, 2026 (2,545 trading days) it fell at least that much in one day 196 times before.

What followed earlier moves of this size
After the move Cases Median change Range
5 trading days later 195 +0.89% -20.39% to +23.41%
20 trading days later 193 +2.39% -26.99% to +31.46%
60 trading days later 188 +3.99% -31.78% to +58.85%

The close on November 20, 2026 is 17.32% below the highest close of the last 252 trading days ($169.55 on August 19, 2026). It is the lowest close since that high. Before that high, the last day it closed at least this far below its highest close of the 252 trading days to that day was August 11, 2025.

November 20, 2026 was the first close below the 200-day average ($143.45) since August 12, 2025.

These figures describe what happened after earlier moves in that period. They are not a forecast.

01

XBI ETF today, November 22, 2026: price, news and forecast

As of November 20, 2026, State Street SPDR S&P Biotech ETF (XBI) trades at $140.18. CleaRank rates it Hold with a score of 45/100.

XBI fell 2.73% on November 20, 2026, and closed below its 200-day average of $143.45 for the first time since August 12, 2025. The fund now sits 8.21% below its 50-day average and 6.32% below its 20-day average, and it is 6.32% below its highest close of the last 252 trading days, which was $169.55 on August 19, 2026. The drop matters because the fund has been losing ground for several weeks: CleaRank's score slid from 64 on November 13, 2026 to 45 today, and the rating moved from Buy to Hold on November 16, 2026. The one-year gain of 23.15% still stands, but the recent direction has turned down.

Why the fund fell below its long-term average

The close on November 20, 2026 was the first close below the 200-day average since August 12, 2025, and the price is now 2.28% below that line. The fund fell 2.73% that session on volume 12.0% above its average. This follows a run of weaker sessions: XBI fell 3.27% on November 12, 2026, closing at $151.20, and fell 3.10% on November 16, 2026, closing at $145.88. The fund also closed below its 50-day average on November 12, 2026. The price action is consistent, with each drop lower than the last.

What the momentum readings say

The 14-day RSI sits at 35.4, in the bearish zone but not oversold. The MACD line is negative. The 20-day average is at $149.64, and the 50-day average at $152.71 is above the 200-day average, which is still in an upward slope. That gap of 6.46% between the 50-day and 200-day averages shows the longer trend has not yet rolled over, even as the price has. The short-term picture is weaker than the longer one.

The fund's longer record

Over the past year, XBI is up 23.15%, and year to date it is up 14.97%. Over six months it is up 6.47%, but over three months it is down 15.42%, and over one month it is down 8.25%. The fund has been far from a steady climber. It holds 99.4% healthcare and 0.7% financial services, so its movements track the biotechnology sector closely. It is also an equal-weighted fund, which spreads its assets across many smaller biotech names rather than relying on a few large firms. Its expense ratio of 0.35% costs $35.00 a year on a $10,000 holding, and its distribution yield is 0.35%.

What the CleaRank score reflects

CleaRank rates the fund 45 out of 100, a Hold. The 1-year performance factor is strongly positive, and the cost factor is neutral. The trend and momentum factors are both negative, and momentum is the factor pulling the score down most. The score was 49 on November 19, 2026, after 56 on November 18, 2026, so it has fallen over the last several sessions.

CleaRank score 45/100 (Hold). 7 of 16 checks pass: trend 1 of 4, momentum 1 of 3, fund 3 of 5, track record 2 of 4.

About State Street SPDR S&P Biotech ETF

S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security. Its holdings typically span drug developers, therapeutic innovators, life sciences tools companies, and other biotechnology businesses across different market-cap sizes. S.

02

XBI ETF forecast 2026

The base case is that XBI keeps trading in a weak band while it works back toward its moving averages. For the trend to improve, the price needs to reclaim the 200-day average at $143.45 and then hold above the 20-day average at $149.64, which would show that the recent selling has eased. Until that happens, the trend reading stays negative, with the price below both the 50-day average at $152.71 and the 200-day average. A close back under the 52-week low of $117.11 would be a worse sign, since it would mean the fund has broken its one-year floor. Biotech funds like this one move with sector sentiment and interest-rate expectations, so a shift in those can change the picture quickly. The fund's typical daily move is 2.41%, so sharp swings in both directions are normal for it.

03

XBI support and resistance levels

Support sits at the 52-week low of $117.11, the nearest floor below the price and the level a fall would meet first. Resistance sits first at the 200-day average of $143.45, which the price just dropped below; a rebound would need to win it back. Next above is the 20-day average at $149.64, then the 50-day average at $152.71, and finally the 52-week high of $169.89. The 200-day average is the most closely watched level now, because the fund's position relative to it has changed in the last session.

XBI support and resistance levels
Level What it is Price From the price
Resistance 4 52-week high $169.89 +21.2%
Resistance 3 50-day moving average $152.71 +8.9%
Resistance 2 20-day exponential average $149.64 +6.8%
Resistance 1 200-day moving average $143.45 +2.3%
Price November 20, 2026 $140.18
Support 1 52-week low $117.11 -16.5%

Technical indicators

Technical rating Bearish 1 of 4 signals bullish
  • RSI Bearish
  • SMA cross Bullish
  • Price vs SMA Bearish
  • MACD Bearish
Momentum Bearish
35.414-day RSI
Oversold <30 Neutral Overbought >70
MACD (12, 26) -2.56 Bearish
Trend Golden cross
-8.2%price against the 50-day average
200-day $143.45 50-day $152.71 Price $140.18
Price against the 200-day -2.3% Bearish

XBI technical analysis in depth

Volatility, momentum, trend strength and the price levels that matter for XBI, calculated by CleaRank from daily bars to November 20, 2026.

Volatility

On the 20-day Bollinger Bands (2 standard deviations) the bands run from $141.22 to $162.16 around a middle of $151.69, and XBI's close of $140.18 sits below the lower band, a stretched reading.

Band width is 13.8% of the price, in the middle of its range over the last 120 sessions.

The 14-day average true range is $4.921, or 3.5% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 5.3% from the close.

Momentum and volume

The 14-day stochastic reads 2 (signal line 6): the close is near the bottom of its two-week range, an oversold zone.

The MACD line (12, 26) is -2.56 against a signal line (9) of -1.22, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 5 sessions ago.

Volume in the latest session was 1.1 times its 20-day average.

Trend strength

The 14-day ADX is 15, under 20: no strong trend in either direction, though sellers have the edge (+DI 15, -DI 29).

On the weekly chart the 10-week average ($151.27) is above the 40-week average ($143.45), a rising longer-term trend, and the weekly RSI is 43.

Key levels

The nearest resistance from the price history is $146.09 (+4.2%): the price turned here 4 times, most recently on November 6, 2026.

The nearest support is $138.21 (-1.4%): the price turned here 3 times, most recently on May 29, 2026.

The largest swing of the last 120 sessions ran up from $127.12 (June 3, 2026) to $169.89 (August 25, 2026); the nearest Fibonacci retracement to the price is the 61.8% level at $143.46.

Classic pivot points for the next session, from November 20, 2026: pivot $141.85, resistance $143.83 and $147.48, support $138.20 and $136.22.

XBI key price levels
Level Price From the price What it is
Resistance (swing high) $162.89 +16.2% the price turned here 3 times, most recently on October 29, 2026
Upper Bollinger Band $162.16 +15.7% 20-day average + 2 standard deviations
Fibonacci 23.6% $159.80 +14.0% retracement of the rise from $127.12 to $169.89
Fibonacci 38.2% $153.55 +9.5% retracement of the rise from $127.12 to $169.89
Resistance (swing high) $153.07 +9.2% the price turned here 3 times, most recently on September 24, 2026
Fibonacci 50.0% $148.51 +5.9% retracement of the rise from $127.12 to $169.89
Pivot R2 (classic) $147.48 +5.2% next-session level
Resistance (swing high) $146.09 +4.2% the price turned here 4 times, most recently on November 6, 2026
Pivot R1 (Fibonacci) $144.00 +2.7% 38.2% of the last range above the pivot
Pivot R1 (classic) $143.83 +2.6% next-session level
Fibonacci 61.8% $143.46 +2.3% retracement of the rise from $127.12 to $169.89
Pivot point $141.85 +1.2% average of the last high, low and close
Lower Bollinger Band $141.22 +0.7% 20-day average - 2 standard deviations
Price $140.18 close, November 20, 2026
Pivot S1 (Fibonacci) $139.70 -0.3% 38.2% of the last range below the pivot
Support (swing low) $138.21 -1.4% the price turned here 3 times, most recently on May 29, 2026
Pivot S1 (classic) $138.20 -1.4% next-session level
Fibonacci 78.6% $136.27 -2.8% retracement of the rise from $127.12 to $169.89
Pivot S2 (classic) $136.22 -2.8% next-session level
Support (swing low) $131.63 -6.1% the price turned here 2 times, most recently on February 25, 2026
Support (swing low) $127.22 -9.2% the price turned here 7 times, most recently on June 3, 2026

Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.

04

XBI ETF price and trading

XBI share price

Start $113.83 Nov 20, 2025
Latest close $140.18 Nov 20, 2026
High $169.55 Aug 19, 2026
Low $113.83 Nov 20, 2025
05

XBI fund facts and valuation

XBI Fund Facts

State Street SPDR S&P Biotech ETF is an exchange-traded fund that provides targeted exposure to U.S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security.

Issuer
State Street Investment Management
Category
Health
Inception
Jan 31, 2006
Expense ratio
0.35%
Net assets
$10.36B
Distribution yield
0.35%
YTD total return to Oct 31 (fund family)
28.00%
Turnover
71.00%

Sector weights

Healthcare 99.4%
Financial Services 0.7%

Total returns to Oct 31, 2026, as the fund family reports them

Period XBI
YTD 28.00%
1 month -1.10%
3 months 6.06%
1 year 38.85%
3 years 33.31%
5 years 4.70%
10 years 10.94%

Key statistics

Net Assets
10.36B
Expense Ratio
0.35%
Yield
0.35%
Day High
$145.50
Day Low
$139.87
52 Week High
169.89
52 Week Low
117.11
06

XBI price history and drawdowns

Risk profile

Daily volatility
2.41%
30-day standard deviation
52-week range
$140.18
$117.11 44% of the way up $169.89

Worst falls and recoveries

Worst fall, last 10 years
-60.8%
February 2021 to May 2022
Recovery
51 months
back at the old peak by August 2026
From the 10-year high
-17.3%
peak with dividends reinvested, August 2026
1-year holds that gained
61%
of every 1-year window

Growth of $10,000

XBI today
$23,248
from $10,000 in December 2016, dividends reinvested
S&P 500 today
$36,764
the same $10,000 in SPY, dividends reinvested
Behind the index by
$13,515
0.6x the index result
Total change
+132%
2.3x the starting amount
XBI S&P 500 (SPY)

Against the market: XBI trailed the S&P 500 over this period: $23,248 against $36,764.

A $10,000 investment in XBI in December 2016 would be worth about $23,248 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).

07

XBI price prediction 2030

XBI 2030 Scenarios (Monte Carlo)

Price today
$140
Base case, 2030
$184
1.3x over 4 years
Range, 2030
$81.23 to $416
10th to 90th percentile

CleaRank's simulation projects a price near $184 for XBI by 2030 in the base case, from $140 today (1.3x over 4 years). The 10th-percentile path ends near $81.23. These are outcomes of a Monte Carlo simulation run on XBI's historical return distribution, not price targets, and they assume no dividends are reinvested.

XBI simulated price paths by year
Year 10th percentile Base case 90th percentile range base today
2027 $99.71 $150 $226
2028 $90.09 $161 $286
2029 $84.68 $172 $349
2030 $81.23 $184 $416
08

XBI ETF forecast: questions people ask

XBI Forecast: Frequently Asked Questions

What is the XBI ETF forecast?
XBI is in a downtrend: at $140.18 it sits below both its 50-day average of $152.71 and its 200-day average of $143.45. The nearest level below the price is the 52-week low of $117.11, and the nearest level above it is the 200-day average at $143.45. No analyst targets exist for the fund, so these levels and the trend are the main reference points.
Is XBI a buy or sell today?
CleaRank rates XBI Hold with a score of 45 out of 100, down from 49 on November 19, 2026. The trend is negative, with the price below its 50-day and 200-day moving averages ($152.71 and $143.45), and the 14-day RSI is 35.4. No analysts rate the fund, so these ratings and figures describe its current condition only.
How far has XBI fallen from its high?
The close on November 20, 2026 is 17.32% below the highest close of the last 252 trading days, which was $169.55 on August 19, 2026. The 52-week high is $169.89, and the fund is 17.49% below it. The November 20 close is the lowest close since that high.
What does the fund hold?
The fund holds 99.4% healthcare and 0.7% financial services, so it is almost entirely tied to the healthcare sector. It tracks the S&P Biotechnology Select Industry Index and uses an equal-weighted approach. Its launch date was January 31, 2006.
How much does XBI cost to own each year?
The expense ratio is 0.35%, which comes to $35.00 a year on a $10,000 holding. The distribution yield is also 0.35%. The cost factor is neutral in CleaRank's score.
What happened after similar one-day drops in the past?
Between October 6, 2016 and November 20, 2026 (2,545 trading days), XBI fell at least 2.73% in one day 196 times. Five trading days later the median move was +0.89% across 195 cases, with a range from -20.39% to +23.41%. These are past outcomes, not a forecast.
How does XBI perform over longer periods?
Over the past year the fund is up 23.15%, and over three years its average yearly return was 33.31% as reported by the fund family. Over three months it is down 15.42%. The three-year figure is as reported by the fund family at its last month-end.

How these figures are computed, and where the data comes from: CleaRank methodology.

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. The ETF analysis and AI-generated insights presented for XBI are for educational and informational purposes only and do not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. ETFs are subject to market risk, including the possible loss of principal. ETF performance depends on the underlying index or assets it tracks, and past performance does not guarantee future results. Expense ratios, tracking error, and liquidity vary by fund. Simulated scenarios and historical performance figures shown are hypothetical and hindsight-based. Market data is provided "as-is" and may be delayed by up to a minute. Investors should read the fund prospectus carefully before investing. Consult a qualified financial advisor for personalized guidance. Analysis generated on November 22, 2026.